Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 9

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 9
---
 Israel), to
study the effect of MEAI on treating obesity and metabolic syndrome, to examine MEAI's metabolic efficacy on appetite regulation, obesity,
and related comorbidities under acute and chronic settings. The results demonstrated that MEAI treatment (i) significantly reduced diet
induced obesity (DIO) and adiposity by preserving lean mass and decreasing fat mass; (ii) exhibited positive effects on glycemic control
by attenuating DIO-induced hyperglycemia, glucose intolerance, and hyperinsulinemia; (iii) reduced DIO-induced hepatic steatosis by decreasing
hepatic lipid accumulation and lowered liver triglyceride and cholesterol levels, primarily by inhibiting de novo lipid synthesis, and
demonstrating that metabolic phenotyping revealed that MEAI increased energy expenditure and fat utilization while maintaining food consumption
similar to that of the vehicle-treated group; and (iv) normalized voluntary locomotion actions without any over stimulatory effects. These
findings provided compelling evidence for the anti-obesity effects of MEAI treatment and highlighted the potential of MEAI as a novel
therapeutic approach for treating obesity and its associated metabolic disorders, offering hope for the development of new treatment options
for this global health challenge.

<div align='center'>2</div>

Additionally, we
have engaged Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel)
to advance the evaluation of MEAI as a potential treatment for addictions and other binge behaviors. Prof. Yadid, a prominent figure in
the research and development of treatments for psychiatric disease, specifically drug addiction, depression, and PTSD, and his team conducted
a series of studies to explore the mechanism of action and specific neural targets of MEAI to evaluate its efficacy as a potential therapeutic
agent in the treatment of addiction and related behaviors. The results of pre-clinical research studies suggested that MEAI may be effective
in the treatment of substance addiction and specifically cocaine without interrupting the natural reward process. According to the United
Nations Office on Drugs and Crime’s “2022 World Drug Report”, of the estimated 284 million people who had used drugs
in the past year, approximately 13.6%, 38.6 million, are estimated to have suffered from drug use disorders. While some addictions, such
as drugs and alcohol, are more concerning than others, addiction and compulsive behavior is not limited to these substances. Compulsive
consumption of